Stablepoint Partners LLC Has $1.38 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Stablepoint Partners LLC cut its position in AstraZeneca PLC (NASDAQ:AZN) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,993 shares of the company’s stock after selling 939 shares during the period. Stablepoint Partners LLC’s holdings in AstraZeneca were worth $1,375,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. lifted its stake in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares in the last quarter. Capital Performance Advisors LLP bought a new position in AstraZeneca in the 3rd quarter valued at about $28,000. Ashton Thomas Securities LLC acquired a new position in AstraZeneca during the 3rd quarter valued at about $45,000. Albion Financial Group UT increased its holdings in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after purchasing an additional 248 shares in the last quarter. Finally, Hollencrest Capital Management raised its stake in shares of AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after purchasing an additional 192 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Up 0.7 %

AZN stock opened at $69.06 on Monday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The stock has a market cap of $214.16 billion, a P/E ratio of 33.04, a P/E/G ratio of 1.13 and a beta of 0.46. The stock’s fifty day simple moving average is $66.44 and its two-hundred day simple moving average is $74.17. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.87 earnings per share. Analysts expect that AstraZeneca PLC will post 4.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.